Amylin Said to Draw Bids of $25 to $29 a Share in First Round

Amylin Said to Draw Bids of $25 to $29 a Share in First Round

of Eli Lilly & Co. via Bloomberg

The suitors gave ranges for their bids, with some offering $25 to $28 a share and others $26 to $29, said one person. Such bids would value Amylin, whose treatments include the diabetes drugs Bydureon and Byetta, at $4.1 billion to $4.7 billion, based on the shares outstanding as of April 26.